Reuters logo
New form of Roche's Esbriet approved in Europe for lung disorder
2017年6月27日 / 凌晨5点13分 / 5 个月前

New form of Roche's Esbriet approved in Europe for lung disorder

ZURICH, June 27 (Reuters) - Roche said a new Esbriet tablet formulation was approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF), a fatal condition that causes irreversible, progressive scarring of the lungs.

Esbriet has been shown to slow the progression of IPF, and the new tablet formulation reduces the number of pills patients need to take, the Swiss drugmaker said in a statement on Tuesday.

Reporting by Silke Koltrowitz; Editing by Michael Shields

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below